| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5648333 | TAKEDA PHARMS USA | Peptides having bradykinin antagonist action |
Jul, 2014
(9 years ago) | |
Firazyr is owned by Takeda Pharms Usa.
Firazyr contains Icatibant Acetate.
Firazyr has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Firazyr are:
- US5648333
Firazyr was authorised for market use on 25 August, 2011.
Firazyr is available in injectable;subcutaneous dosage forms.
Firazyr can be used as treatment of pathological state by antagonizing bradykinin receptor including treatment of acute attacks of hereditary angioedema (hae).
Drug patent challenges can be filed against Firazyr from 26 August, 2015.
The generics of Firazyr are possible to be released after 25 August, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-14) | Aug 25, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 25, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 25, 2018 |
Drugs and Companies using ICATIBANT ACETATE ingredient
NCE-1 date: 26 August, 2015
Market Authorisation Date: 25 August, 2011
Treatment: Treatment of pathological state by antagonizing bradykinin receptor including treatment of acute attacks of hereditary angioedema (hae)
Dosage: INJECTABLE;SUBCUTANEOUS
FIRAZYR family patents
